Photosensitization Study in Androgenetic Alopecia

Learn more about:
Related Clinical Trial
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss Anti-Androgen Treatment for COVID-19 A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss The Effect of Platelet Rich Plasma on Non-scarring Alopecia Optimizing Parameters for Long-pulsed Nd:YAG Laser for Reducing Hair Shaft Diameter HairDx Analytical Validation Study The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899) A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931) A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669) A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541) To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study To Evaluate the Pharmacokinetics and Safety of AD-208 The Utility of Platelet Rich Plasma in Hair Loss Computer-Assisted Versus Manual Hair Harvest Comparative Study Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512) PAI-1 Expression in Non-scarring Hair Loss Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Cold Plasma to Treat Hair Loss Adipose-derived SVF for Treatment of Alopecia Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss Photosensitization Study in Androgenetic Alopecia Point-of-Care Adipose-derived Cells for Hair Growth Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Modulated Light Therapy in Participants With Pattern Hair Loss Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia N-Acetyl-Cysteine for Treatment of AGA in Men Clinical Trial in Females for Female Pattern Hair Loss Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5% Treatment of Androgenetic Alopecia in Males and Females Microarray Analysis of Scalp Biopsies After Minoxidil Treatment Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis 24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Minoxidil Response Testing in Males With Androgenetic Alopecia Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Treatment of Androgenetic Alopecia in Females, 9 Beam Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Treatment of Androgenetic Alopecia in Males Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Treatment of Androgenetic Alopecia in Females, 12 Beam Nanofat Grafting for Treatment of Androgenetic Alopecia Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females Treatment of Androgenic Alopecia in Males A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia Androgenetic Alopecia and the JAK-STAT Pathway Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia

Brief Title

Photosensitization Study in Androgenetic Alopecia

Official Title

A Within-subject, Randomized, Evaluator-blinded, Vehicle-controlled Study to Assess the Photosensitization Potential of Finasteride Cutaneous Solution(P-3074) in Human Subjects

Brief Summary

      This study evaluates the potential for induction of photosensitization by P-3074 0.25%
      finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a
      negative control (0.9% sodium chloride, NaCl)
    

Detailed Description

      Healthy male volunteers, drawn from the general population, will be treated with P-3074
      solution, placebo vehicle control and 0.9% sodium chloride USP (negative control) by using 6
      induction applications on the back area and Ultraviolet A (UVA)/Ultraviolet B (UVB)
      irradiations during the 3 week induction period, a 10 day rest period, and a challenge phase
      of a 24-hour patch application, UVA and UVB irradiation followed by evaluation of
      photosensitization over the subsequent 72 hours.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Potential for induction of photosensitization


Condition

Androgenetic Alopecia

Intervention

Finasteride 0.25%

Study Arms / Comparison Groups

 Finasteride 0.25%
Description:  approximately 0.2 ml of P-3074 (0.25% finasteride)

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

58

Start Date

May 9, 2016

Completion Date

June 27, 2016

Primary Completion Date

June 2016

Eligibility Criteria

        Inclusion Criteria:

          1. Males aged 18 to 65.

          2. Good general health, as assessed by verbal medical history and brief physical
             examination of the skin.

          3. Fitzpatrick Skin Type I-IV, determined by interview at screening.

          4. Willing to use a double-barrier methods (for example, a condom or a diaphragm plus
             spermicide) during sexual intercourse with a female partner while participating in the
             study.

          5. Male subjects will need to confirm method and length of time for method of birth
             control for female partners.

          6. Fully informed of the risks of entering the study and willing to provide written
             consent to enter the study.

          7. Willing to follow study rules, which include: no sun exposure (for example, no
             swimming, sunbathing, or tanning beds), avoidance of activities that would cause
             excessive sweating, no use of lotions, creams, or oils on the back area

          8. Must be willing not to change current brand of personal care products such as soaps,
             body washes, laundry detergent, body sprays, body spritzes, etc. while participating
             on the study.

        Exclusion Criteria:

          1. MED ≤ 2.5 SED for Fitzpatrick Skin Types I and II or MED ≤ 4.0 SED for Fitzpatrick
             Skin Types III and IV

          2. Type I Insulin-dependent diabetes

          3. Mastectomy for cancer involving removal of lymph nodes draining the test site.

          4. Clinically significant skin diseases which may contraindicate participation, including
             psoriasis, eczema, atopic dermatitis, and active skin cancer.

          5. Use of any photosensitizing medications or supplements, such as but not limited to
             sulfa drugs, tetracyclines, phenothiazines, thiazides, antiemetics and St. John's
             Wort.

          6. Any medical conditions caused or affected by sunlight (UV), such as but not limited to
             solar urticarial and polymorphous light eruptions.

          7. Active immunologic disorders.

          8. Routine use of anti-inflammatory, immunosuppressive or antihistamine medications (81
             mg aspirin is acceptable).

          9. Participation in a patch test or soap chamber test within the past 4 weeks.

         10. History of significant sensitivity or allergy to adhesive bandages, tapes, etc.

         11. Use of finasteride (oral and/or topical), within 6 months prior to the screening
             visit.

         12. Contraindications to finasteride therapy or intolerance of finasteride.

         13. History of sensitivity to skin solution products.

         14. Hair, tattoos, pigmentation, scars, moles or other conditions at the areas to be
             patched that may interfere with patch application, tolerability, or postapplication
             evaluations.

         15. Participation in a clinical trial or receipt of an investigational medication within 4
             weeks of the study.

         16. Current treatment with allergy injections.

         17. History of severe asthma.

         18. Chronic or active liver disease [alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) > 1.5x upper limit of normal (ULN)]

         19. Neutrophils < 1500 cells/mm3

         20. Clinically significant chronic illness, which could place the subject at increased
             risk during participation or result in inappropriate dermal response during the study
             in the opinion of the Investigator.

         21. History of alcohol or drug abuse within 1 year of the study.

         22. Any condition the Investigator believes would interfere with the evaluation of the
             subject, or may put the subject at undue risk.

         23. Judged by the investigator to be unsuitable for any reason.
      

Gender

Male

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Michael Carr, MD, , 

Location Countries

United Kingdom

Location Countries

United Kingdom

Administrative Informations


NCT ID

NCT02791243

Organization ID

PM1542


Responsible Party

Sponsor

Study Sponsor

Polichem S.A.


Study Sponsor

Michael Carr, MD, Principal Investigator, Princeton Consumer Research Inc.


Verification Date

May 2017